Antibiotic Regimens Tailored by Clinical Pharmacist Suppored by Intensivist Enhanced Rational Use of Antibiotics

Critical Illness Clinical Trial

Official title:

Antibiotic Regimens Tailored by Clinical Pharmacist Suppored by Intensivist Enhanced Rational Use of Antibiotics

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04931914
• Other study ID #: 203
• Status: Completed
• Start date: January 4, 2020
• Est. completion date: December 25, 2020

Study information

• Verified date: November 2022
• Source: University of Alexandria
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

adding pharmaceutical services to patient care and changing the professional activity of pharmacists from drug-focused to patient-oriented care,in the current study, clinical pharmacists will be assigned to monitor pharmacotherapy regimens, participate in patient care, and cooperate in educating the staff and evaluating care.

Description:

During the intervention period, the pharmacist attended daily unit rounds with ICU intensivist with a focus on optimization of antibiotic regimens. Pharmacist consultative services were also available by phone calls 24 hours x 7 days if needed. For every patient surgical prophylactic antibiotic initiated immediately before surgery and continued for 48 hours following surgery. Antibiotic therapy had given as either directed or empiric. Directed therapy was defined as treatment of a documented infection based on culture and sensitivity. Empiric therapy was defined as any antibiotic therapy administered when no documented infection was present, and the patient had clinically suspected infection following surgery. Empiric antibiotic administration was required in majority of our SICU patients. Antibiotics had given after exclusion of allergy by history and intradermal sensitivity test.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 300
• Est. completion date: December 25, 2020
• Est. primary completion date: December 5, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• all admitted patients to the ICU between age 18-80 years old

Exclusion Criteria:

• Patient admitted for less than 24 hours (including deaths and transfers) will be excluded from the study.

Pediatric patients weighted less than kilograms.

Related Conditions & MeSH terms

• Critical Illness

Intervention

Other:
• Clinical pharmacy sharing in the patient care regimen
antibiotic regimens will be directed by a trained clinical pharmacist recommendation and supported by intensivist.

Locations

Country	Name	City	State
Egypt	Alexandria university	Alexandria

Sponsors (1)

Lead Sponsor	Collaborator
University of Alexandria

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antibiotics consumption	consumption will be counted as number of defined daily doses (DDD), expressed as DDD per 100 patient-days	1 year
Primary	Average length of stay	the average number of days that patients spent in SICU.	1 year
Primary	Mortality rate	The number of deaths of patients admitted to SICU, divided by the number of admissions.	1 year